A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
Mihaela Cristea, Daphne Stewart, Timothy W. Synold, Nora Ruel, Joanne Mortimer, Wenge Wang, Alexander Jung, Sharon P. Wilczynski, Gottfried E. Konecny, Melissa Eng, Lindsay Kilpatrick, Ernest Han, Thanh H. Dellinger, Amy Hakim, Stephen Lee, Robert J. Morgan, Mark T. Wakabayashi, Paul Frankel
Topics & Concepts
MedicineGemcitabineInternal medicineNeutropeniaGastroenterologyTriple-negative breast cancerOvarian cancerGynecologic oncologyOncologyFallopian tube cancerMucositisEndometrial cancerFebrile neutropeniaChemotherapyBreast cancerCancerOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyEndometrial and Cervical Cancer Treatments